Detecting Cancer Early 2017-05-22T12:40:46+00:00
1 in 4

One in four of us will be diagnosed with cancer in our lifetime.

Detecting cancer early
is life changing

At Cirina we are pioneering products
that detect cancer at its earliest stages
and empower you to take action.

Cirina Logo

Our Story

DNA helix

Our science is driven by the passion and life long work of Cirina co-founder Dennis Lo, DM, DPhil. In 1997, Dr. Lo was the first scientist to discover the presence of fetal DNA in a pregnant mother’s blood (plasma). Since his first discovery, Dennis Lo and his colleagues, Rossa Chiu and Allen Chan have been continuously at the forefront of the field. Their pioneering work has made non-invasive blood-based prenatal testing possible. Today, non-invasive prenatal tests empower millions to make informed decisions for their families.

Cancer ribbon

In the two decades since 1997, Dennis Lo’s pioneering work has enabled simple blood-based alternatives to challenging biopsy-based diagnostic tests for conditions like pregnancy, transplantation, cancer and organ damage. Cirina is now bringing the power of such cutting edge research to you, your family and your loved ones. Imagine a world where we routinely detect cancer at the earliest stages when it is most curable.

Our Science

Dr. Lo’s scientific publications and clinical studies have shown that selected cancers may be detected at the earliest stages by testing for tumor DNA in apparently healthy individuals (Cancer, 2013 May 15;119(10):1838-44). These discoveries have profound implications for curing cancer by treating the disease at its most vulnerable stage.

Cancer Journal Cover

Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.

PNAS Journal Cover

Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments.

Clinical Chemistry Journal Cover

Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing

PNAS Journal Cover

Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients.

Cancer Research Journal Cover

Quantitative Analysis of Cell-free Epstein-Barr Virus DNA in Plasma of Patients with Nasopharyngeal Carcinoma.

Dr. Lo was named a 2016 Thomson Reuters Citation Laureate, in recognition of the high citations of his research work, ranking him in the top 0.1% of his field worldwide. He also received the 2016 Future Science Prize in life science for his seminal contributions to the field of non-invasive blood-based diagnoses. The Future Science Prize is widely recognized as a Chinese version of the Nobel Prize.

Our Team

Maneesh Jain
Maneesh JainPhD

Cirina’s leadership team combines an established track record of breakthrough scientific innovation and entrepreneurial success. Our team has been at the forefront of two seminal advances within the past two decades:

  • The understanding of the science and biology of plasma tumor DNA
  • The development of technologies and pioneering products to analyze the human genome

Together, our team is unlocking a new era of precision medicine that will transform the way we detect, treat, and ultimately, cure these devastating diseases.

Dennis Lo
Dennis LoDM, DPhil

Join Us

Cirina is currently actively recruiting top scientific and business talent to join its quest to detect devastating diseases like cancer at their earliest stages and empower people to take action. We bring diverse backgrounds from leading academic institutions and genomics technology companies.

Are you interested in…

  • Contributing to curing cancer?
  • Doing the best work of your life in a team dedicated to doing the same?
  • Innovating at the forefront of cancer biology and genomics technology?
  • Coming to work each day in a supportive and intellectually stimulating environment?

If so, contact us today at joinus@cirina.com.

Cirina detecting cancer early